With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor||Northwestern University (Illinois) / Rintaro Hashizume, MD/PhD||Reach Grants||2018||Illinois|
|Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies||The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD||Reach Grants||2018||Maryland|
|Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD||Reach Grants||2018||Washington|
|Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma||University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD||Reach Grants||2017||North Carolina|
|Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors||Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD||Reach Grants||2017||New York|
|Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML||Children's Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD||Reach Grants||2017||Wisconsin|
|DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Reach Grants||2016||Pennsylvania|
|Targeting PLK1 as a Common Mechanism in Ph-like ALL||University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD||Reach Grants||2016||Texas|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Utah / Michael Engel, MD/PhD||Reach Grants||2016||Utah|
|Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma||Children's Hospital of Philadelphia / John Maris, MD||Reach Grants||2016||Pennsylvania|